Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
5.43M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
3.61M
-
Shares change
-
-1.35M
-
Total reported value, excl. options
-
$10.4M
-
Value change
-
-$8.43M
-
Put/Call ratio
-
0.74
-
Number of buys
-
18
-
Number of sells
-
-19
-
Price
-
$2.87
Significant Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q4 2021
50 filings reported holding APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share as of Q4 2021.
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.61M shares
of 5.43M outstanding shares and own 66.43% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (697K shares), PURA VIDA INVESTMENTS, LLC (434K shares), KENNEDY CAPITAL MANAGEMENT, INC. (337K shares), MORGAN STANLEY (326K shares), RENAISSANCE TECHNOLOGIES LLC (282K shares), BlackRock Inc. (232K shares), JPMORGAN CHASE & CO (195K shares), CITADEL ADVISORS LLC (163K shares), GEODE CAPITAL MANAGEMENT, LLC (150K shares), and PDT Partners, LLC (143K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.